B7-H3 (CD276) as a Radioligand Therapy Target
B7-H3 (CD276), CD276 molecule, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, B7-H3 staining is highest in skin cancer (100% of samples positive), endometrial cancer (100% of samples positive) and head and neck cancer (100% of samples positive). Clinical status: Clinical-stage (up to phase 1, any modality), with 1 active clinical trial.
Is B7-H3 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in skin cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: Clinical-stage (up to phase 1, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
B7-H3 expression in cancer
Protein expression of B7-H3 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Skin Cancer | 0.83 | High | 100% |
| Endometrial Cancer | 0.77 | High | 100% |
| Head and Neck Cancer | 0.75 | High | 100% |
| Prostate Cancer | 0.75 | High | 100% |
| Melanoma | 0.69 | High | 100% |
| Bladder Cancer | 0.61 | High | 100% |
| Lung Cancer | 0.61 | High | 100% |
| Glioma | 0.61 | High | 100% |
| Breast Cancer | 0.58 | High | 100% |
| Pancreatic Cancer | 0.56 | High | 100% |
| Gastric Cancer | 0.53 | High | 100% |
| Ovarian Cancer | 0.53 | High | 100% |
| Cervical Cancer | 0.50 | Medium | 92% |
| Liver Cancer | 0.44 | Medium | 83% |
| Thyroid Cancer | 0.42 | Medium | 100% |
| Colorectal Cancer | 0.39 | Medium | 83% |
| Testicular Cancer | 0.33 | Medium | 80% |
| Kidney Cancer | 0.17 | Low | 50% |
| Neuroendocrine Tumors | 0.17 | Low | 50% |
| Lymphoma | 0.08 | Low | 25% |
Is B7-H3 internalized?
Nuclens has not yet extracted internalization evidence for B7-H3. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
B7-H3 clinical trials
Clinical-stage (up to phase 1, any modality). 1 active trial reference B7-H3 (ClinicalTrials.gov, accessed 2026-09-07).
B7-H3 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See B7-H3 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
B7-H3 gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -0.20 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related skin cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · SSTR2 · ITGB6 · HER2 (ERBB2) · ITGAV · Mesothelin (MSLN)
See all radioligand therapy targets in skin cancer.
See how B7-H3 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.